Navigating FDA's CMC Expectations For Cell And Gene Therapy

By Rajiv Gangurde, Ph.D., Vice President Technical - Regulatory Consulting; Christiane Niederlaender, Ph.D., Vice President, Technical, Regulatory Consulting; Kurt Brorson, Ph.D., Vice President, Technical, Regulatory Consulting

Manufacturing is where cell and gene therapies win—or stall. Unlike traditional drugs, these living, highly variable products demand bespoke chemistry, manufacturing, and controls (CMC) strategies that can scale without sacrificing quality or safety. As the field advances, FDA’s expectations are evolving to balance innovation with robust oversight—emphasizing product characterization, comparability, control strategies, and long‑term reliability across the manufacturing lifecycle.

This piece distills the FDA’s evolving CMC approach for cell and gene therapies and what it means for sponsors building high‑velocity programs. It highlights where regulatory flexibility exists (e.g., phase‑appropriate CMC, risk‑based controls) and where precision is non‑negotiable (identity, potency, sterility, viral safety, and process consistency). It also outlines practical levers—earlier CMC planning, analytics that scale, digital release readiness, tech transfer discipline, and proactive FDA engagement—that de‑risk development and keep timelines on track.

With the right CMC strategy, sponsors can align with FDA expectations, streamline reviews, and bring advanced therapies to patients faster—confidently and compliantly.